Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

614 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.
Williams SV, Vusirikala A, Ladhani SN, Fernandez Ruiz De Olano E, Iyanger N, Aiano F, Stoker K, Gopal Rao G, John L, Patel B, Andrews N, Dabrera G, Ramsay M, Brown KE, Lopez Bernal J, Saliba V. Williams SV, et al. Among authors: john l. Euro Surveill. 2021 Jul;26(27):2100626. doi: 10.2807/1560-7917.ES.2021.26.27.2100626. Euro Surveill. 2021. PMID: 34240699 Free PMC article.
Cross-sectional observational study of epidemiology of COVID-19 and clinical outcomes of hospitalised patients in North West London during March and April 2020.
Gopal Rao G, Allen A, Papineni P, Wang L, Anderson C, McGregor A, Whittington A, John L, Harris M, Hiles S, Nicholas T, Adams K, Akbar A, Blomquist P, Decraene V, Patel B, Manuel R, Chow Y, Kuper M; London North West Healthcare Trust COVID-19 Research Group. Gopal Rao G, et al. Among authors: john l. BMJ Open. 2021 Feb 18;11(2):e044384. doi: 10.1136/bmjopen-2020-044384. BMJ Open. 2021. PMID: 33602712 Free PMC article.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kanji N, Libri V, Llewelyn MJ, McGregor AC, Maallah M, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Bawa T, Saralaya D, Sharma S, Sheridan R, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550261 Free PMC article. Clinical Trial.
Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study.
Houston H, Deas G, Naik S, Shah K, Patel S, Greca Dottori M, Tay M, Filson SA, Biggin-Lamming J, Ross J, Vaughan N, Vaid N, Gopal Rao G, Amin AK, Gupta-Wright A, John L. Houston H, et al. Among authors: john l. BMJ Open. 2021 Aug 9;11(8):e049179. doi: 10.1136/bmjopen-2021-049179. BMJ Open. 2021. PMID: 34373308 Free PMC article.
Experience of a novel community testing programme for COVID-19 in London: Lessons learnt.
Wallis G, Siracusa F, Blank M, Painter H, Sanchez J, Salinas K, Mamuyac C, Marudamuthu C, Wrigley F, Corrah T, Rampling T, Logan S, Goodman A, Miller D, Williams B, McGregor A, Parris V, Sandhu G, John L, Papineni P, Whittington A. Wallis G, et al. Among authors: john l. Clin Med (Lond). 2020 Sep;20(5):e165-e169. doi: 10.7861/clinmed.2020-0436. Epub 2020 Jul 17. Clin Med (Lond). 2020. PMID: 32680837 Free PMC article.
Increase in disseminated TB during the COVID-19 pandemic.
Barrett J, Painter H, Rajgopal A, Keane D, John L, Papineni P, Whittington A. Barrett J, et al. Among authors: john l. Int J Tuberc Lung Dis. 2021 Feb 1;25(2):160-166. doi: 10.5588/ijtld.20.0846. Int J Tuberc Lung Dis. 2021. PMID: 33656432 No abstract available.
614 results